Trial Profile

Phase 4 clinical trial assessing AD-101

Status: Planning

Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AD 101 AmyriAD (Primary)
Indications Alzheimer's disease
Focus Therapeutic Use

Most Recent Events

08 Jun 2022 New trial record
01 Jun 2022 According to AmyriAD media release, under terms of the new contract, which is valued at nearly $1.0 million, Societal will execute a range of clinical trial services to support the initiation of Phase 3 and this Phase 4 clinical studies of AD101.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com